ClearPoint Neuro opened at $10.69, in line with its previous close of $10.69. In the last trading session, the stock traded between $10.00 and $10.69. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in ClearPoint Neuro is now worth
$ 60.78
resulting in a loss of
$ 39.22 (39.22%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.52 (-4.87%)
Day High
$10.69
Day Low
$10.00
Day Open
$10.69
Prev Close
$10.69
Volume
3,22,906
1W Return
9.80%
1M Return
-13.64%
3M Return
-27.97%
6M Return
-1.65%
1Y Return
-57.82%
Fundamentals
Market Cap ($ Mn)
326
PE Ratio
-
PB Ratio
43.97
PEG Ratio
-
ROE
-117.14%
ROCE
-49.25%
EPS (TTM)
$-0.23
Investment Returns
1 Week
9.80%
1 Month
-13.64%
3 Months
-27.97%
6 Months
-1.65%
9 Months
-24.23%
Financials
Quarterly
All values in $ Mn
9.2
Jun 25
8.9
Sep 25
10.4
Dec 25
12.1
Mar 26
10.9
Jun 26
12.1
Sep 26
Updates
15Oct
ClearPoint Neuro to announce Q3FY26 results on October 28
ClearPoint Neuro schedules Q3FY26 earnings release for October 28, 2026. Conference call scheduled for 4:30 pm ET after market close. Replay available until November 27, 2026 via phone and online archive.
ClearPoint Neuro reduces FY2026 sales guidance to $48.000M-$52.000M, missing the $53.133M estimate. The cut from the prior $52.000M-$56.000M range signals potential commercial headwinds and a cautious outlook on full-year performance.
ClearPoint Neuro missed Q2 analyst estimates with EPS of $(0.38) versus $(0.29) and sales of $10.880 million versus $12.733 million, reflecting wider losses and slower top-line growth than expected despite strategic investments.
2mo ago
1Aug
Aspen Neuroscience wins FDA RMAT designation for Parkinson's cell therapy
ClearPoint Neuro announced that partner Aspen Neuroscience secured FDA RMAT designation for sasineprocel, an investigational autologous cell therapy for Parkinson's disease. The designation allows for expedited review and early FDA interaction. ClearPoint's navigation system supports the ASPIRO trial, contributing to a portfolio of over 60 partner programs.
3mo ago
22Jul
ClearPoint Neuro to announce Q2 2026 results on August 3
ClearPoint Neuro, Inc. announced it will release its Q2 2026 financial results on August 3, 2026, followed by a conference call. A replay will be available until September 2, 2026.
3mo ago
18Jun
B. Riley Securities raises ClearPoint Neuro target to $30
B. Riley Securities analyst Anderson Schock maintained a Buy rating on ClearPoint Neuro and raised the price target to $30 from $20.
